Eli Lilly And Co vs Vanguard Information Technology Index Fund ETF — how do they compare? Eli Lilly And Co trades at $1,163.89 (market cap $1.02T), while Vanguard Information Technology Index Fund ETF trades at $115.93. The key difference: Eli Lilly And Co pays a 0.6% dividend while Vanguard Information Technology Index Fund ETF pays none. Which is the better fit depends on your goals.
| LLY | VGT | |
|---|---|---|
Market Cap | $1.02T | — |
Sector | Health | — |
52-Week High | $1.24K | $125.77 |
52-Week Low | $625.65 | $83.59 |
Enterprise Value | $1.06T | — |
Dividend Yield | 0.6% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
VGT trades at $113.23, showing minimal daily movement with a 0.11% gain. Technical indicators signal a bearish trend with moving averages and overall signals pointing downward, though oscillators remain neutral. The ETF recently completed a 1:8 stock split and has a small dividend scheduled for June 2026. Recent news highlights strong historical performance but notes current semiconductor sector volatility affecting tech ETFs.
The outlook for VGT remains tied to technology sector momentum, particularly AI and semiconductor growth. Key risks include sector concentration and valuation concerns after recent run-ups. Analyst sentiment appears mixed, balancing strong long-term track record against near-term technical weakness and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →